DE69940735D1 - Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen - Google Patents

Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen

Info

Publication number
DE69940735D1
DE69940735D1 DE69940735T DE69940735T DE69940735D1 DE 69940735 D1 DE69940735 D1 DE 69940735D1 DE 69940735 T DE69940735 T DE 69940735T DE 69940735 T DE69940735 T DE 69940735T DE 69940735 D1 DE69940735 D1 DE 69940735D1
Authority
DE
Germany
Prior art keywords
physiologically active
active substance
biodegradable
release
arrangements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940735T
Other languages
English (en)
Inventor
Sankaram Bhima Mantripragada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69940735D1 publication Critical patent/DE69940735D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
DE69940735T 1998-07-17 1999-07-16 Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen Expired - Lifetime DE69940735D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9324398P 1998-07-17 1998-07-17
US10185598P 1998-09-25 1998-09-25
US12309799P 1999-03-05 1999-03-05
PCT/US1999/016239 WO2000003660A1 (en) 1998-07-17 1999-07-16 Biodegradable compositions for the controlled release of encapsulated substances

Publications (1)

Publication Number Publication Date
DE69940735D1 true DE69940735D1 (de) 2009-05-28

Family

ID=27377463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940735T Expired - Lifetime DE69940735D1 (de) 1998-07-17 1999-07-16 Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen

Country Status (12)

Country Link
US (2) US6277413B1 (de)
EP (1) EP1098610B1 (de)
JP (2) JP2002520120A (de)
AT (1) ATE428371T1 (de)
AU (1) AU752225B2 (de)
CA (1) CA2338031C (de)
DE (1) DE69940735D1 (de)
ES (1) ES2325141T3 (de)
IL (2) IL140899A0 (de)
NO (1) NO20010264L (de)
NZ (1) NZ509186A (de)
WO (1) WO2000003660A1 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4575592B2 (ja) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
CA2276066A1 (en) * 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
US7118921B1 (en) * 1999-06-24 2006-10-10 Mcmaster University Incorporation and applications of biomolecular interactions within a carrier
US7025980B1 (en) * 1999-09-14 2006-04-11 Tepha, Inc. Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
DE19949897A1 (de) 1999-10-15 2001-04-19 Rainer Rogasch Formkörper und Verfahren zu dessen Herstellung
ES2226933T3 (es) * 1999-11-01 2005-04-01 John Rhodes Composicion para tratar el estreñimiento y el sindrome del intestino irritable.
CA2410052A1 (en) * 2000-06-02 2001-12-13 Zycos Inc. Delivery systems for bioactive agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
JP3990880B2 (ja) * 2001-07-10 2007-10-17 キヤノン株式会社 ポリヒドロキシアルカノエート被覆リポソームの製造方法
ES2294147T5 (es) † 2001-07-27 2011-04-04 N.V. Nutricia Composiciones enterales para la prevención y/o tratamiento de la sepsis.
US6488952B1 (en) * 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
KR100527408B1 (ko) * 2002-01-03 2005-11-09 한국과학기술원 카프로락톤과 락티드의 랜덤공중합체와 폴리에테르를이용한 생분해성 블록공중합체의 제조방법 및 이의 응용
US20040071780A1 (en) * 2002-01-16 2004-04-15 Lillard James W. PACE-A microspheres for delivery of antigens
EP1485070A1 (de) 2002-03-13 2004-12-15 Novartis AG Pharmazeutische mikropartikel
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
KR100573289B1 (ko) * 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6998074B1 (en) 2002-08-30 2006-02-14 Microfab Technologies, Inc. Method for forming polymer microspheres
US20040052836A1 (en) * 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
WO2004034975A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
EP1585504A4 (de) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
US7736391B2 (en) 2003-02-06 2010-06-15 Tonaba Healthscience Ii, Llc Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
SE527505C2 (sv) * 2003-06-10 2006-03-28 Anna Imberg Komposita material och partiklar
US20060188573A1 (en) * 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
KR100663880B1 (ko) 2004-02-12 2007-01-03 한국과학기술연구원 고분자-지질 조성물, 구조체 및 이들의 제조방법
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
EP1781264B1 (de) 2004-08-04 2013-07-24 Evonik Corporation Verfahren zur herstellung von abgabevorrichtungen und damit erhaltene vorrichtungen
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
WO2006053031A2 (en) * 2004-11-12 2006-05-18 Mayo Foundation For Medical Education And Research Photocrosslinkable poly(caprolactone fumarate)
JP4897699B2 (ja) * 2004-11-18 2012-03-14 メイヨ フオンデーシヨン フオー メデイカル エジユケーシヨン アンド リサーチ ポリカプロラクトンとポリ（プロピレンフマレート）とのブロックコポリマー
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1874525B1 (de) * 2005-04-29 2011-06-01 Mayo Foundation for Medical Education and Research Hydrophile/hydrophobe polymernetze auf der basis von poly(caprolactonfumarat), poly(ethylenglycolfumarat) und copolymere davon
US20070005213A1 (en) * 2005-06-30 2007-01-04 Hyundai Autonet Co., Ltd. Backward control for automobiles using telematics and method thereof
WO2007035938A2 (en) 2005-09-22 2007-03-29 Medivas, Llc BIS-(α-AMINO)-DIOL-DIESTER-CONTAINING POLY(ESTER AMIDE) AND POLY(ESTER URETHANE) COMPOSITIONS AND METHODS OF USE
WO2007038246A2 (en) 2005-09-22 2007-04-05 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
EP2044142A2 (de) * 2006-06-29 2009-04-08 Medtronic, Inc. Poly(orthoester)polymere sowie herstellungs- und verwendungsverfahren dafür
EP3421031A1 (de) 2006-08-09 2019-01-02 Intarcia Therapeutics, Inc Osmotisches verabreichungssystem mit kolbenanordnung
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
US20100151436A1 (en) * 2007-03-02 2010-06-17 Fong Peter M Methods for Ex Vivo Administration of Drugs to Grafts Using Polymeric Nanoparticles
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
EP2162120B1 (de) 2007-06-04 2016-05-04 Bend Research, Inc Nanopartikel mit nicht ionisierbarem zellulosepolymer und amphipilem nicht ionisierbarem blockcopolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
CA2709412A1 (en) * 2007-07-24 2009-01-29 Medivas, Llc Biodegradable cationic polymer gene transfer compositions and methods of use
US8568445B2 (en) 2007-08-21 2013-10-29 St. Jude Medical Puerto Rico Llc Extra-vascular sealing device and method
US8333787B2 (en) 2007-12-31 2012-12-18 St. Jude Medical Puerto Rico Llc Vascular closure device having a flowable sealing material
US20090068743A1 (en) * 2007-08-23 2009-03-12 Medivas, Llc Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
EP2039352A1 (de) * 2007-09-18 2009-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lipid-Nanokapseln mit wässrigem Kern zur Einkapselung hydrophiler und/oder lipophiler Moleküle
EP2231169B1 (de) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmazeutische zusammensetzungen mit nanopartikeln und resuspensionsmaterial
WO2009073216A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
EP2222281B1 (de) 2007-12-20 2018-12-05 Evonik Corporation Verfahren zur herstellung von mikropartikeln mit geringer restlösemittelmenge
US8840640B2 (en) * 2007-12-31 2014-09-23 St. Jude Medical Puerto Rico Llc Vascular closure device having an improved plug
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8940315B2 (en) * 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
CA2722743A1 (en) 2008-04-28 2009-11-05 Zogenix, Inc. Novel formulations for treatment of migraine
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) * 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8877242B2 (en) 2008-07-14 2014-11-04 Polypid Ltd. Sustained-release drug carrier composition
AU2009289529B2 (en) 2008-09-04 2015-05-28 Amylin Pharmaceuticals, Llc Sustained release formulations using non-aqueous carriers
EA016540B1 (ru) * 2008-12-30 2012-05-30 Ооо "Научно-Производственный Комплекс "Наносистема" Фармацевтическая композиция для лечения туберкулеза, способ ее получения и способ лечения туберкулеза
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
IN2012DN00570A (de) 2009-07-14 2015-06-12 Polypid Ltd
IN2012DN02656A (de) * 2009-09-17 2015-09-11 Evonik Degussa Corp
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
CN102892406B (zh) 2010-01-19 2015-04-08 波利皮得有限公司 缓释核酸基质组合物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103748139B (zh) 2011-06-23 2016-08-17 帝斯曼知识产权资产管理有限公司 用于递送生物活性剂的包含生物可降解的聚酯酰胺共聚物的微米颗粒或纳米颗粒
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US8716363B2 (en) * 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
RU2664700C2 (ru) 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения
MX366048B (es) * 2012-08-02 2019-06-26 Polypid Ltd Composiciones y métodos para el tratamiento de vacíos óseos y fracturas expuestas.
EP2981285B1 (de) 2013-04-03 2020-06-03 N-Fold Llc Neuartige nanopartikelzusammensetzungen
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20170326073A1 (en) * 2014-11-25 2017-11-16 Cbc Co., Ltd. Janus nanoparticle and method for producing the same
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
SG10201913699QA (en) 2016-05-16 2020-03-30 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CN110234696B (zh) 2017-01-30 2022-05-31 生物辐射实验室股份有限公司 乳液组合物及其使用方法
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона
EP3701943A1 (de) * 2019-02-26 2020-09-02 CAPNOMED GmbH Verzögerte abgabe von antikrebsmitteln
US20230210763A1 (en) * 2019-09-19 2023-07-06 Amw Gmbh Extruded depot form for controlled active substance release
KR20230115591A (ko) * 2022-01-27 2023-08-03 주식회사 티온랩테라퓨틱스 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305158A (en) 1884-09-16 devore
US723583A (en) 1902-12-13 1903-03-24 Ephraim Chabot Adjustable shade-roller holder.
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
DE3585967D1 (de) 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
US5141674A (en) 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
DE3682257D1 (de) 1985-11-22 1991-12-05 Takeda Chemical Industries Ltd Liposomzusammensetzung.
US5244678A (en) 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4861597A (en) 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
US4877619A (en) 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
DK86988A (da) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
JP2727326B2 (ja) * 1988-08-03 1998-03-11 ライオン株式会社 温度感応性微小球体
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
KR960005137B1 (ko) * 1989-11-13 1996-04-22 노바 파머수티컬 코포레이션 물질 전달용 리포스피어
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
US5977326A (en) 1991-08-06 1999-11-02 Salford Ultrafine Chemicals And Research Limited Process for making morphine-6-glucuronide or substituted morphine-6-glucuronide
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
JPH06247842A (ja) 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5455044A (en) 1993-05-14 1995-10-03 Depotech Corporation Method for treating neurological disorders
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
KR100365979B1 (ko) 1993-10-13 2003-07-22 다윈 디스커버리 리미티드 레보부피바카인또는그염을포함하는마취제용약제학적조성물
GB9321061D0 (en) 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use
US5849763A (en) 1993-10-13 1998-12-15 Darwin Discovery Limited Use of levobupivacaine as an anesthetic agent
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5451408A (en) 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US6048545A (en) 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
SE9402453D0 (sv) 1994-07-12 1994-07-12 Astra Ab New pharmaceutical preparation
DE4430592A1 (de) 1994-08-20 1996-02-22 Max Delbrueck Centrum Liposomale Zubereitung, ihre Herstellung und ihre Verwendung
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic Inc Verfahren und vorrichtung zur verabreichung von analgetika
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
JP3191004B2 (ja) * 1995-12-15 2001-07-23 武田薬品工業株式会社 マイクロスフェアの製造法
GB9605915D0 (en) 1996-03-21 1996-05-22 Univ Bruxelles Liposome encapsulated amphiphilic drug compositions
US5808573A (en) 1996-08-01 1998-09-15 Nec Electronics Incorporated Methods and structure for sampled-data timing recovery with reduced complexity and latency
AU3981097A (en) * 1996-08-21 1998-03-06 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
CA2276269C (en) 1996-10-15 2008-09-02 The Liposome Company, Inc. N-acyl phosphatidylethanolamine-mediated liposomal drug delivery
WO1998024415A1 (en) 1996-12-02 1998-06-11 The Regents Of The University Of California A bilayer structure which encapsulates multiple containment units and uses thereof
US5767627A (en) 1997-01-09 1998-06-16 Trusi Technologies, Llc Plasma generation and plasma processing of materials
US5865184A (en) 1997-01-13 1999-02-02 Takiguchi; Tetsuo Combined spinal and epidural anesthesia
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
GB9704352D0 (en) 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
GB9704351D0 (en) 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
DE69806246T3 (de) 1997-03-13 2006-05-18 Campbell, James N. Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
EP1009390A4 (de) 1997-07-02 2004-05-06 Euro Celtique Sa Verlängerte narkose in gelenken und körperzwischenräumen
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US5945435A (en) 1997-07-21 1999-08-31 Darwin Discovery Limited Levobupivacaine and its use
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US20010004644A1 (en) 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
EP0998287B1 (de) 1997-07-22 2003-05-07 Darwin Discovery Limited Verwendung von levobupivacain
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
FR2932229B1 (fr) 2008-06-05 2011-06-24 Renault Sas Pilotage de l'alimentation electrique d'une bougie d'allumage d'un moteur a combustion interne
US8683976B2 (en) 2011-02-16 2014-04-01 Ford Global Technologies, Llc Spark plug degradation detection
EP2502696B1 (de) 2011-03-22 2014-02-12 Agie Charmilles SA Verfahren und Vorrichtung zur digitalen Datenübertragung

Also Published As

Publication number Publication date
EP1098610B1 (de) 2009-04-15
US6793938B2 (en) 2004-09-21
JP2011063596A (ja) 2011-03-31
AU5003099A (en) 2000-02-07
US20010048945A1 (en) 2001-12-06
EP1098610A1 (de) 2001-05-16
IL140899A0 (en) 2002-02-10
ES2325141T3 (es) 2009-08-26
AU752225B2 (en) 2002-09-12
ATE428371T1 (de) 2009-05-15
NZ509186A (en) 2005-01-28
CA2338031C (en) 2006-12-05
IL140899A (en) 2007-05-15
EP1098610A4 (de) 2003-09-03
WO2000003660A1 (en) 2000-01-27
CA2338031A1 (en) 2000-01-27
NO20010264L (no) 2001-03-06
JP2002520120A (ja) 2002-07-09
NO20010264D0 (no) 2001-01-16
US6277413B1 (en) 2001-08-21

Similar Documents

Publication Publication Date Title
DE69940735D1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
Ganji et al. Hydrogels in controlled drug delivery systems
Chen et al. Enhancement of periodontal tissue regeneration by locally controlled delivery of insulin-like growth factor-I from dextran–co-gelatin microspheres
US4855134A (en) Sustained-release preparation
BR9808933A (pt) Composição sob forma de microcápsulas ou de implantes, processo de preparação de uma substância hidrossolúvel, substância ativa, acetato de triptorelina, acetato de lanreotìdeo, ou acetato de octreotìdeo, e rna de filamento duplo
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
NZ501950A (en) Medicinal compositions for application to mucosa
DE3850823T2 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode.
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
WO2003099225A3 (en) Compositions for delivering nucleic acids to cells
EP0138216B1 (de) IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
JPS60231609A (ja) リポソ−ム製剤
DE60126433D1 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
Chien et al. Transdermal controlled administration of indomethacin. I. Enhancement of skin permeability
NO20092662L (no) Sammensetning med forlenget frigjoring og fremgangsmate for a produsere det samme
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
Graham et al. Polymeric inserts and implants for the controlled release of drugs
HRP20080178T3 (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
DZ3473A1 (fr) Formulation pharmaceutique a liberation prolongee independante de la force ionique.
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
KR20160036557A (ko) 겔 타입 단백질이 있는, 혈소판 및/또는 성장 인자가 풍부한 혈액 조성물의 제제, 및 그의 제조 방법
ATE298256T1 (de) Biomaterial in form von mikropartikeln von hyaluronsaure zur medizinischen verwendung
JP2019523302A (ja) 腋臭を治療する方法

Legal Events

Date Code Title Description
8364 No opposition during term of opposition